• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

    20.88 +0.54 (+2.65%)
    Streaming Delayed Price Updated: 10:14 AM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 237,977
    Open 20.38
    Bid (Size) 20.86 (300)
    Ask (Size) 20.90 (200)
    Prev. Close 20.34
    Today's Range 20.38 - 21.22
    52wk Range 8.580 - 22.73
    Shares Outstanding 69,484,053
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -2.0%
    -2.0%
    1 Month
    +4.5%
    +4.5%
    3 Month
    +26.9%
    +26.9%
    6 Month
    +138.6%
    +138.6%
    1 Year
    +52.5%
    +52.5%

    More News

    Read More
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    News headline image
    Syndax Pharmaceuticals's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗
    Via Stocktwits
    News headline image
    Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Announces Participation in November Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Why Is Syndax Stock Down Today? ↗
    Via Benzinga
    News headline image
    Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Where Syndax Pharmaceuticals Stands With Analysts ↗
    Via Benzinga
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
    Via Benzinga
    News headline image
    This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
    Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
    What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
    The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 20.88
    When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 01/07/26 10:14 AM ET
    What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.45B
    How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
    Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.